Oral semaglutide therapy for 3 months in patients with HFpEF and T2DM significantly reduced log BNP levels compared to the pre-treatment period (mean difference -0.35; 95% CI -0.44 to -0.11; p<0.001).
Cohort (n=27)
No
Does oral semaglutide reduce BNP levels in patients with HFpEF and T2DM?
Three-month oral semaglutide therapy in patients with HFpEF and T2DM is associated with significant reductions in BNP and improvements in systemic inflammation and echocardiographic parameters.
Effect estimate: mean difference -0.35 (95% CI -0.44 to -0.11)
p-value: p=<0.001
Background: The clinical impact of oral semaglutide on cardiac biomarkers in real-world patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) remains unclear. We evaluated whether initiation of oral semaglutide was associated with a reduction in B-type natriuretic peptide (BNP) levels and explored factors associated with this response. Methods: We retrospectively enrolled 27 patients with HFpEF who initiated oral semaglutide for T2DM management at a single academic center. Clinical data were collected at three time points: three months before treatment initiation (pre-treatment period), at initiation (baseline), and three months after semaglutide initiation (on-treatment period). The primary outcome was the change in the common logarithm of BNP levels (log BNP) during the on-treatment versus pre-treatment period. Results: Median age was 67 (59, 78) years and 21 (77.8%) were men. Log BNP remained stable during the pre-treatment period (p = 0.34) but decreased significantly during the on-treatment period (p < 0.001). The reduction in log BNP during the on-treatment period was significantly greater than during the pre-treatment period (mean difference −0.35, 95% confidence interval −0.44 to −0.11, p < 0.001). Concomitant reductions were observed in HbA1c, body weight, C-reactive protein, left atrial volume index, and left ventricular mass index. Changes in C-reactive protein levels were significantly correlated with those in log BNP (r = 0.46, p = 0.015). Conclusions: In patients with HFpEF and T2DM, three-month oral semaglutide therapy was associated with reductions in BNP, as well as improvements in glycemic control, systemic inflammation, left atrial volume index, and left ventricular mass index.
Hida et al. (Mon,) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) (n=27). Oral semaglutide vs. Pre-treatment period was evaluated on Change in the common logarithm of BNP levels (log BNP) during the on-treatment versus pre-treatment period (mean difference -0.35, 95% CI -0.44 to -0.11, p=<0.001). Oral semaglutide therapy for 3 months in patients with HFpEF and T2DM significantly reduced log BNP levels compared to the pre-treatment period (mean difference -0.35; 95% CI -0.44 to -0.11; p<0.001).